| 7.29 -0.5 (-6.42%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.31  |
1-year : | 16.23 |
| Resists | First : | 11.39 |
Second : | 13.89 |
| Pivot price | 9.01 |
|||
| Supports | First : | 7.34 |
Second : | 6.11 |
| MAs | MA(5) : | 8.18 |
MA(20) : | 9.42 |
| MA(100) : | 8.45  |
MA(250) : | 5.04 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 7.8 |
D(3) : | 12.8 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 16.23 | Low : | 1.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NKTX ] has closed above bottom band by 17.6%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.9 - 7.95 | 7.95 - 7.98 |
| Low: | 7.22 - 7.28 | 7.28 - 7.33 |
| Close: | 7.7 - 7.79 | 7.79 - 7.87 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Mon, 08 Apr 2024
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX ... - Business Wire
Fri, 05 Apr 2024
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors - Business Wire
Tue, 02 Apr 2024
Nkarta Announces Departure of Chief Financial & Business Officer - Quantisnow
Wed, 27 Mar 2024
Should Biotechnology Stock Nkarta Inc (NKTX) Be in Your Portfolio Wednesday? - InvestorsObserver
Mon, 25 Mar 2024
Nkarta: NK Cell Therapy Advancement On Two Fronts (NASDAQ:NKTX) - Seeking Alpha
Mon, 25 Mar 2024
Nkarta Announces Pricing of $240 Million Underwritten Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 73.5 (%) |
| Shares Short | 4,850 (K) |
| Shares Short P.Month | 4,240 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -36.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -86 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -3.25 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|